CytomX Therapeutics (CTMX) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Join SI Premium – FREE
CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $11.84 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Micron Technology price target to $1,300
- Societe Generale SA (GLE:FP) (SCGLY) PT Raised to EUR83 at JPMorgan
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
